Chinese herbal medicine for ulcerative colitis: product-level clinical evidence, mechanistic appraisal, and a roadmap to precision translation
- 1Foshan Hospital of Traditional Chinese Medicine , , ,
- 2Guangzhou University of Chinese Medicine , ,
- 3The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Zhongshan Hospital , , ,
Abstract
Chinese herbal medicine (CHM) is widely used for ulcerative colitis (UC), but product heterogeneity, variable trial quality, and limited long-term safety data preclude class-level efficacy claims. This critical narrative review therefore evaluates evidence at the level of the defined botanical drug product, formulation, route, dose, and manufacturing process. The review focuses on traditional formulas, processed botanical drugs, and proprietary preparations with documented use in Chinese medical practice. Purified plant metabolites such as curcumin and common flavonoids are not treated as uniquely Chinese interventions; they are discussed only when they are part of a defined CHM-related product or when pivotal natural-product trials provide a relevant product-level comparator. Primary randomized trials show heterogeneous results: higher-dose curcumin trials and the curcumin-QingDai combination provide signals of benefit, low-dose curcumin was negative, and indigo naturalis shows dose-related efficacy accompanied by important safety concerns. Mechanistically, the strongest evidence comes from human target engagement or causal perturbation, exemplified by mucosal CYP1A1 induction with curcumin-QingDai and loss of indigo naturalis efficacy in Ahr-deficient mice. Most other mechanistic claims remain preclinical and model-dependent. Translation requires taxonomically authenticated and chemically characterized products, measured exposure, causal mechanism testing, objective CORE-IBD/STRIDE-II-aligned outcomes, CONSORT-CHM reporting, and prospective, batch-traceable pharmacovigilance. No molecular, microbial, or traditional-pattern biomarker has yet shown a prospectively validated treatment-by-biomarker interaction for a defined CHM product. Precision translation should therefore be regarded as a prospective research program rather than an achieved clinical state.
Related
- Multi-omics integration for precision tuberculosis medicine: from molecular atlases to clinical translation
- Modulating Th17-driven inflammation in ulcerative colitis with Chinese medicine: pathways, cytokines and beyond.
- Targeting convergent pathogenic pathways: precision nutrition and lifestyle strategies in ulcerative colitis
- Mechanistic investigation of clarithromycin in ulcerative colitis involving Kv1.3 downregulation and modulation of the Th17/Treg balance
- High-resolution HLA and MICA/MICB typing of the 1000 Genomes panel: a resource for precision medicine
BibTeX
@article{wu2026chinese,
title = {{Chinese herbal medicine for ulcerative colitis: product-level clinical evidence, mechanistic appraisal, and a roadmap to precision translation}},
author = {Yingxiu Wu and Jianxiong Ren and Huibiao Li and Shiyu Qi and Wei Ke},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1976448},
url = {https://europepmc.org/article/PMC/PMC13687833},
note = {CC BY},
}
RIS
TY - JOUR
TI - Chinese herbal medicine for ulcerative colitis: product-level clinical evidence, mechanistic appraisal, and a roadmap to precision translation
AU - Yingxiu Wu
AU - Jianxiong Ren
AU - Huibiao Li
AU - Shiyu Qi
AU - Wei Ke
PY - 2026
DA - 2026/10/08
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1976448
UR - https://europepmc.org/article/PMC/PMC13687833
AB - Chinese herbal medicine (CHM) is widely used for ulcerative colitis (UC), but product heterogeneity, variable trial quality, and limited long-term safety data preclude class-level efficacy claims. This critical narrative review therefore evaluates evidence at the level of the defined botanical drug product, formulation, route, dose, and manufacturing process. The review focuses on traditional formulas, processed botanical drugs, and proprietary preparations with documented use in Chinese medical practice. Purified plant metabolites such as curcumin and common flavonoids are not treated as uniquely Chinese interventions; they are discussed only when they are part of a defined CHM-related product or when pivotal natural-product trials provide a relevant product-level comparator. Primary randomized trials show heterogeneous results: higher-dose curcumin trials and the curcumin-QingDai combination provide signals of benefit, low-dose curcumin was negative, and indigo naturalis shows dose-related efficacy accompanied by important safety concerns. Mechanistically, the strongest evidence comes from human target engagement or causal perturbation, exemplified by mucosal CYP1A1 induction with curcumin-QingDai and loss of indigo naturalis efficacy in Ahr-deficient mice. Most other mechanistic claims remain preclinical and model-dependent. Translation requires taxonomically authenticated and chemically characterized products, measured exposure, causal mechanism testing, objective CORE-IBD/STRIDE-II-aligned outcomes, CONSORT-CHM reporting, and prospective, batch-traceable pharmacovigilance. No molecular, microbial, or traditional-pattern biomarker has yet shown a prospectively validated treatment-by-biomarker interaction for a defined CHM product. Precision translation should therefore be regarded as a prospective research program rather than an achieved clinical state.
SN - 1663-9812
ER -